



**Cerba HealthCare, Medical Biology International Group, announces its intention to launch an increase to its incremental term loan facilities and a share capital increase, the proceeds of which will partly be used to fund the acquisition of Groupe Bio7.**

Cerba HealthCare intends to meet with investors this month with a €408 million offering of its incremental term loan facilities. This offering is being made as part of a broader financing package to fund (i) the acquisition of Groupe Bio7 and the repayment of certain of its indebtedness, (ii) seven other bolt-on acquisitions in 2018, consisting of small labs, (iii) the repayment of the amounts currently drawn under the RCF, and (iv) the expenses and fees in connection with these transactions. In addition to the €408 million increase in the incremental term loan facilities, the debt financing package will include €60 million of unsecured committed financing.

Apart from the loan facilities, these transactions will be funded by an equity contribution of € 115 million, evidencing the strong support of the shareholders. **This combination will make these acquisitions leverage neutral for Cerba HealthCare.**

As announced previously, Cerba HealthCare has signed an exclusive agreement for the purchase of Groupe Bio7, which is one of the leading multi-location clinical pathology groups in France. Groupe Bio7 is expected to contribute €48 millions of pro forma EBITDA including run rate cost savings and synergies to Cerba HealthCare's pro forma adjusted EBITDA which will be at € 219 million for the twelve months ended December 31, 2017, after giving pro forma effect to the acquisition of Groupe Bio7 and the other seven smaller bolt-on acquisitions in 2018.

\*\*\*\*\*

Contact :

Pascale LAURENT  
Communication Director  
pascale.laurent@cerbahealthcare.com